Omnicell (OMCL) Stock Overview
Provides healthcare technology in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for OMCL from our risk checks.
OMCL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Omnicell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$41.42 |
| 52 Week High | US$55.00 |
| 52 Week Low | US$22.66 |
| Beta | 0.86 |
| 1 Month Change | 24.09% |
| 3 Month Change | -14.60% |
| 1 Year Change | 31.99% |
| 3 Year Change | -36.51% |
| 5 Year Change | -70.38% |
| Change since IPO | 335.54% |
Recent News & Updates
Recent updates
OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle
Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing
Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing
Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.
OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside
Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside
Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
Feb 12
OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market
Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance
Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile
Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.OMCL: New Medication Management Platform Will Support Future Upside Potential
Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.OMCL: Share Repurchases Will Support Future Upside Potential
Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside
Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Nov 13OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position
Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.Omnicell Q2 Earnings: Market Ignoring The Segments
Jul 31Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
Jul 16Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 28Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
May 14US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
May 09Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Apr 07Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Mar 20Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Feb 14Omnicell Q4 Earnings: Ignore The Short-Term Noise
Feb 12Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 09Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Jan 28Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues
Nov 27Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next
Nov 02Omnicell Q3 Earnings: Look At The Growth Segment
Nov 01Is It Time To Consider Buying Omnicell, Inc. (NASDAQ:OMCL)?
Oct 31Is Omnicell (NASDAQ:OMCL) Using Too Much Debt?
Oct 07Shareholder Returns
| OMCL | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 13.9% | -4.0% | 0.6% |
| 1Y | 32.0% | -16.1% | 28.7% |
Return vs Industry: OMCL exceeded the US Medical Equipment industry which returned -18.1% over the past year.
Return vs Market: OMCL exceeded the US Market which returned 27.6% over the past year.
Price Volatility
| OMCL volatility | |
|---|---|
| OMCL Average Weekly Movement | 9.9% |
| Medical Equipment Industry Average Movement | 8.3% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: OMCL has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: OMCL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 3,580 | Randy Lipps | www.omnicell.com |
Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services.
Omnicell, Inc. Fundamentals Summary
| OMCL fundamental statistics | |
|---|---|
| Market cap | US$1.96b |
| Earnings (TTM) | US$20.43m |
| Revenue (TTM) | US$1.23b |
Is OMCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMCL income statement (TTM) | |
|---|---|
| Revenue | US$1.23b |
| Cost of Revenue | US$687.59m |
| Gross Profit | US$537.47m |
| Other Expenses | US$517.04m |
| Earnings | US$20.43m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.45 |
| Gross Margin | 43.87% |
| Net Profit Margin | 1.67% |
| Debt/Equity Ratio | 13.4% |
How did OMCL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/30 19:28 |
| End of Day Share Price | 2026/04/30 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omnicell, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |